Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation

被引：23
|
作者：
Ru, Yuhua [1 ,2 ]
Chen, Jia [1 ,2 ]
Wu, Depei [1 ,2 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Suzhou 215006, Peoples R China
[2] Soochow Univ, Collaborat Innovat Ctr Hematol, Inst Blood & Marrow Transplantat, Suzhou 215006, Peoples R China
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2018年 / 101卷 / 03期
基金：
美国国家科学基金会; 国家重点研发计划;
关键词：
EB virus; hematopoietic stem cell transplantation; lymphoproliferative disease; BONE-MARROW-TRANSPLANTATION; EBV REACTIVATION; RISK-FACTORS; VIRAL LOAD; PREEMPTIVE RITUXIMAB; PROLONGED HYPOGAMMAGLOBULINEMIA; ALLOGENEIC TRANSPLANTATION; HEART-TRANSPLANTATION; EUROPEAN CONFERENCE; PEDIATRIC-PATIENTS;
D O I：
10.1111/ejh.13131
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Epstein-Barr virus (EBV) viremia and post-transplant lymphoproliferative disease (PTLD) are severe complications after hematopoietic stem cell transplantation (HSCT). A series of risk factors have been found to predict EBV viremia and PTLD, including the T-cell depletion, reduced intensity conditioning, and alternative donor. The rituximab pre-emptive therapy could improve PTLD prognosis significantly, but the trigger of initiating rituximab pre-emptive therapy has not been well established. Additionally, EBV-specific cytotoxic T cell (CTL) is a promising approach to treat EBV-PTLD.
引用
收藏
页码：283 / 290
页数：8
相关论文
共 50 条
  • [31] Epstein-Barr Virus (EBV) Discordance: The Tale of a Pulmonary Post-transplant Lymphoproliferative Disorder (PTLD) in a Heart Transplant Recipient
    Alpizar-Rivas, R. M.
    Mathers, E.
    Hay, C. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [32] Epstein-Barr Virus Infection and Lymphoproliferative Disorder After Hematopoietic Cell Transplantation
    Zhong, Yazhen
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2012, 16 (02) : 211 - 214
  • [33] Risk factors for Epstein Barr virus-related post-transplant lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation
    Uhlin, M.
    Wikell, H.
    Sundin, M.
    Blennow, O.
    Mauerer, M.
    Ringden, O.
    Winiarski, J.
    Ljungman, P.
    Remberger, M.
    Mattsson, J.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S48 - S48
  • [34] Epstein-Barr virus-associated post-transplant lymphoproliferative disorder
    Bar-Natan, M
    Nagler, A
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2006, 8 (03): : 205 - 207
  • [35] Genomic diversity of Epstein-Barr Virus in post-transplant lymphoproliferative disorder
    Martinez, Olivia
    Maloney, Eden
    Busque, Vincent
    Hui, Sin Ting
    Esquivel, Carlos O.
    Krams, Sheri
    PEDIATRIC TRANSPLANTATION, 2019, 23
  • [36] Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders
    Martin Rowe
    Gerald Niedobitek
    Lawrence S. Young
    Springer Seminars in Immunopathology, 1998, 20 : 389 - 403
  • [37] Successful Preemptive Therapy with Rituximab for Epstein-Barr Virus Infection to Prevent Post-Transplant-Lymphoproliferative Disease after Pediatric Hematopoietic Stem Cell Transplantation
    Kim, B. K.
    Hong, K. T.
    Kang, H. J.
    An, H. Y.
    Choi, J. Y.
    Shin, H. Y.
    Ahn, H. S.
    Park, S. S.
    Lee, J. S.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S222 - S222
  • [38] Epstein-Barr Virus Genome Variation in Post-Transplant Lymphoproliferative Disorder
    Maloney, Eden
    Busque, Vincent A.
    Hui, Sin Ting
    Krams, Sheri M.
    Esquivel, Carlos O.
    Martinez, Olivia M.
    TRANSPLANTATION, 2018, 102 : S95 - S95
  • [39] Genomic Diversity of Epstein-Barr Virus in Post-Transplant Lymphoproliferative Disorder
    Maloney, E.
    Martinez, O.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 402 - 402
  • [40] Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders
    Rowe, M
    Niedobitek, G
    Young, LS
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1998, 20 (3-4): : 389 - 403
12345